Sleep Improvement Protocol for Mid-Life Adults

Prolonged overnight fasting through time-restricted eating (TRE) is being investigated in an RCT as a means to reduce sleep disturbances and improve circadian rhythm stability by reinforcing peripheral clock gene oscillation [id=33]. The TREAD trial (NCT06548191) targets a consolidated eating window to allow extended nighttime fasting, with outcomes including sleep disturbance and cognitive function. The literature reports that eating close to the biological night disrupts CLOCK-BMAL1-driven metabolic cycling [id=44].

Animal research demonstrates that chronic circadian misalignment combined with high-fat and high-fructose dietary patterns amplifies metabolic and organ-level injury, reflecting a synergistic disruption of clock-controlled metabolic genes [id=108]. While direct human insomnia data are limited, the mechanistic overlap between circadian disruption, metabolic dysregulation, and poor sleep quality supports minimising ultra-processed food intake, particularly in the evening. This step provides dietary context for the circadian stabilisation strategy.

The CLOCK-BMAL1 transcription factor complex drives circadian gene expression and determines the timing of sleep propensity; irregular sleep timing disrupts this molecular oscillator and exacerbates insomnia [id=44]. Stabilising bed and wake times to within ±30 minutes daily is reported to reinforce endogenous circadian amplitude. Circadian misalignment has also been linked to oxidative stress pathways that further impair sleep quality [id=133].

Dim-light melatonin onset (DLMO) is the gold-standard circadian marker indicating the start of evening melatonin rise and can identify circadian phase delay or advance common in mid-life insomnia [id=31]. The dlmoR open-source package enables standardised hockey-stick DLMO estimation from salivary or plasma melatonin samples. Knowing individual phase allows personalised timing of light and melatonin interventions rather than generic scheduling.

Slow-wave sleep (SWS) declines with age and its restoration is associated with improvements in mood, cognition, and next-day functioning [id=132]. A pilot RCT at Wake Forest is investigating non-invasive brain stimulation during sleep to augment SWS in adults with comorbid depression, providing mechanistic proof-of-concept for SWS as a modifiable target. Behavioural strategies reported to support SWS include limiting caffeine after noon, avoiding alcohol, and maintaining a cool sleep environment.

OSA is a common and frequently undiagnosed contributor to fragmented, non-restorative sleep in mid-life adults and impairs glymphatic waste clearance linked to cognitive decline [id=43, id=47]. PAP therapy for OSA has been shown in RCT designs to reverse neurocognitive impairment associated with sleep-disordered breathing [id=96]. Mid-life adults presenting with insomnia, snoring, witnessed apnoeas, or unexplained daytime fatigue should be referred for polysomnography or home sleep testing.

Outdoor and indoor lighting conditions have population-level effects on circadian entrainment and melatonin suppression in older and mid-life adults [id=97]. The ENLIGHTENme project is collecting evidence on how light characteristics (spectrum, intensity, timing) affect biological health outcomes, with blue-wavelength light in the evening being the primary suppressor of endogenous melatonin rise [id=31]. Reducing screen-emitted and overhead blue-enriched light in the 2 hours before intended sleep onset is reported to preserve DLMO timing.

Morning bright light is the dominant zeitgeber for the suprachiasmatic nucleus (SCN) circadian pacemaker and drives robust CLOCK-BMAL1 cycling that consolidates the sleep-wake cycle [id=44, id=97]. Population-based lighting research supports outdoor light exposure as a health-relevant intervention with measurable biological outcomes in adults [id=97]. In mid-life adults with delayed circadian phase, morning light is additionally phase-advancing, complementing melatonin-based interventions.

Hyperarousal—cortical and autonomic—is a core perpetuating factor in chronic insomnia and shares mechanistic overlap with disrupted sleep staging, including suppression of slow-wave and REM sleep [id=121, id=132]. Cognitive-behavioural and relaxation-based interventions targeting pre-sleep arousal are designed to reduce this drive. REM sleep generation depends on precisely coordinated brainstem population dynamics [id=121], and arousal-driven fragmentation disrupts this architecture.

Bidirectional interactions between cortical arousal states—including subclinical epileptiform activity and mood disorders—can fragment sleep architecture and reduce sleep depth [id=32, id=132]. In mid-life adults with treatment-resistant insomnia, comorbid depression or unrecognised neurological conditions should be systematically excluded, as these alter the neurobiological substrate of sleep regulation and may require targeted intervention beyond standard sleep hygiene.

Melatonin marks the transition into biological night and its onset timing (DLMO) can be used to precisely time low-dose exogenous melatonin supplementation for phase-advancing or phase-maintaining effects in insomnia [id=31]. Beyond chronobiotic effects, melatonin has been shown to exert immune-metabolic actions via glutathione-dependent pathways, suggesting potential secondary anti-inflammatory benefits relevant to mid-life physiology [id=112]. Supplementation is most evidence-aligned when timed relative to assessed DLMO rather than a fixed clock time.

Physical activity functions as a non-photic zeitgeber that reinforces circadian timing and increases homeostatic sleep pressure (adenosine accumulation), both of which are impaired in chronic insomnia. Circadian misalignment and oxidative stress—pathways targeted by structured light and activity schedules—are mechanistically linked to sleep deficiency [id=133]. Exercise timing in the morning or early afternoon is reported to be most aligned with circadian biology, avoiding late-evening sessions that may elevate core body temperature near the sleep window.

Glymphatic system activity, which clears neurotoxic metabolites during sleep, can be non-invasively assessed via contrast-free MRI DTI-ALPS methodology in research contexts [id=40]. In clinical and self-monitoring contexts, consumer actigraphy or validated sleep diaries provide longitudinal data on sleep efficiency, wake after sleep onset, and total sleep time. Deterioration in these metrics despite adherence should trigger reassessment for OSA or circadian disorder.

Circadian interventions require several weeks to shift endogenous phase, and repeat DLMO assessment allows objective confirmation of phase change and guides dose or timing adjustments for melatonin and light therapy [id=31]. Parallel tracking of sleep efficiency and subjective insomnia severity (e.g. ISI score) provides clinical response data. Non-response at 12 weeks warrants re-evaluation of OSA status, psychiatric comorbidity, or consideration of emerging neuromodulatory protocols [id=132].

Bright light therapy and melatonin manipulation can destabilise mood cycling in individuals with bipolar disorder; SCN-targeted neurostimulation approaches currently under investigation specifically note bipolar disorder as both a target population and a source of metabolic-circadian complexity requiring specialist oversight [id=111]. Sleep deprivation and circadian disruption are known seizure precipitants, and protocols involving sleep scheduling should be implemented cautiously in individuals with known epilepsy or seizure history, given bidirectional sleep-epilepsy interactions [id=32].

Intermittent hypoxia from untreated OSA elevates loop gain and sympathetic tone, which can interact with exercise-induced cardiovascular stress [id=110]. Mid-life adults with suspected or confirmed severe OSA should have PAP therapy initiated or optimised prior to embarking on moderate-to-vigorous exercise components of this protocol. The OSADA trial context further highlights that sleep-disordered breathing can have systemic immune and metabolic consequences that modify the safety profile of non-pharmacological interventions [id=95].